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CHAPTER I 
 
INTRODUCTION 
 
A Synthetic Approach to Vaccination 
 Bacillus anthracis is the rod-shaped, gram positive bacterium responsible for 
causing the disease anthrax.  The anthrax toxin is the major virulence factor and is 
comprised of three protein precursors: protective antigen (PA), edema factor (EF), and 
lethal factor (LF).1  PA and LF combine to form lethal toxin, which carries out 
intracellular hydrolysis of important host protein substrates.  PA and EF combine to form 
edema toxin, which causes extreme swelling and upsets water homeostasis.  Both EF and 
LF depend on PA for membrane transport and activation, making PA crucial for toxicity 
and an excellent drug target.   
 The development of vaccines containing whole pathogens or portions thereof is 
time-consuming, expensive, potentially hazardous to researchers and patients, and runs 
the risk of conformational changes that render the drug inactive.  An ideal substitute 
would be produced from media free of pathogen-derived products that can be fully 
synthesized in a lab and mass-produced.  This provides the perfect opportunity to employ 
biomimetics, or the study of nature for inspiration for designs to solve human problems.  
In this particular case, the design to be mimicked is PA, so a synthetic peptide epitope 
mimic of PA conjugated to an appropriate drug delivery vehicle could provide an 
excellent alternative to the current vaccine.  Several types of antigen carriers are already 
in use, namely large proteins or toxoids such as keyhole limpet hemocyanin (KLH),2 
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ovalbumin,3 bovine serum albumin,4 and tetanus toxoid,5 to name a few.  However, there 
are some very concerning drawbacks to these types of carriers.  Some incite strong 
antibody response against themselves, which can overshadow the immune response 
against the target epitope.  Often, only a few conjugation sites on the protein carrier are 
available for binding to the epitope, so presentation of the peptide is inefficient and 
antigenic sites on the carrier are sometimes left exposed.  Some protein-peptide 
complexes are unstable and lead to the formation of unusable precipitates.  These issues 
give rise to the need for a different type of scaffold to present synthetic peptide epitopes.   
 
Biomimetic Gold Nanoparticles 
An approach to a novel vaccine in the form of a biomimetic gold nanoparticle 
(AuNP) has been explored in the Wright and Cliffel labs.6  Gold is bioinert, and therefore 
would not elicit an immune response against itself.  Nanoparticles can be synthesized to 
resist precipitation, and are multivalent, or possess the ability to be functionalized with 
multiple constituents.  Nanometer-sized, isolable, thiolate ligand-capped metallic 
particles were first reported by Brust et al. in 1994.7  Since then, AuNPs and monolayer-
protected gold clusters (MPCs) have been the subject of much interest because of the 
simplicity of their synthesis, their stability, and the capability to be repeatedly dried down 
and redissolved in common solvents without aggregation.8-11  They display core size-
dependent properties, transitioning from metal-like to molecule-like as core size 
decreases and can be easily characterized by conventional analytical methods.8,9  Perhaps 
most interesting is the ease of functionalization of these particles via well-characterized 
ligand place-exchange reactions in which free ligands in solution exchange with ligands 
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bound to the nanoparticle surface to form a mixed-monolayer.9,12  Ligands Exchange sites 
are not static, meaning that thiolates can migrate across the surface of a particle.12  It is 
for this reason that AuNPs are such a promising scaffold for attachment of peptide 
epitope mimics.  Cysteine-terminated epitopes can be bound to the nanoparticle surface 
as monodentate linear peptides or bidentate loops.  Migration of the two ends of the loop 
across the particle surface allows them to position themselves at the proper distance apart 
for the faithful reconstitution of the epitope’s physiological conformation.  Surface 
accessible loops on proteins are common antibody binding sites, and as PA is a loop-rich 
protein, three peptide epitopes from the C-terminus and two internal loops were 
synthesized and place-exchanged onto a tiopronin-capped MPC in a previous study by 
Gerdon et al.6  The MPC antigen mimics studied are shown in Figure 1.  Binding studies 
were performed on a quartz-crystal microbalance (QCM) and involved subjecting each 
type of particle to seven mouse monoclonal anti-PA antibodies.  The epitope with the 
highest binding affinity was found to be PA680B (bidentate), which was preferred over 
PA680M (monodentate), highlighting the importance of secondary structure in antibody 
recognition.  The development of immunogenic MPCs for in vivo studies detailed below 
utilizes PA680B (loop PA) and PA680M (linear PA).   
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Figure 1. X-ray crystal structure of the protective antigen of B. anthracis (middle) and illustrations of PA 
mimics highlighting the conformational and linear epitopes.  Three known epitopes are highlighted in the 
crystal structure: amino acids 680-692 (red), 703-722 (blue), 730-735 (magenta). Composition of antigen 
mimics are as follows: A) PA680B–MPC; B) PA680M–MPC; C) PA703B–MPC; D) PA730M–MPC. 
Reproduced from Reference 6. 
 
Tiopronin AuNPs as Scaffolds 
Delivery of therapeutics has been limited by solubility issues, low stability, and 
rapid clearance from the body.13  Tiopronin-capped AuNPs are water-soluble, have high 
stability, and their circulation half-life can be tuned via PEG-ylation, making Tio AuNPs 
an excellent candidate for drug delivery agents.  If Tio AuNPs are to be used as a scaffold 
for the PA epitope mimic, it is first necessary to determine the effects of unmodified Tio 
AuNPs in vivo.  Opsonization and phagocytosis are the primary biological processes by 
which foreign particles, including nanoparticles, are removed from the body by the 
mononuclear phagocytic system (MPS), and are important barriers that must be overcome 
if nanoparticles are to be used for drug delivery.13-16  Opsonin proteins in blood serum 
quickly bind to the charged surface of nanoparticles, making them easily recognizable by 
macrophages of the MPS so that they may be removed.  Once phagocytes have engulfed 
the particles, they attempt to degrade it with excretions of enzymes and other oxidative-
reactive chemical factors.  However, nanoparticles are non-biodegradable, so they are 
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either removed by the renal system or sequestered in the MPS organs (liver, spleen, bone) 
if they are above the renal filtration molecular weight threshold of ~100,000 daltons.14  
Opsonized nanoparticles have an increased hydrodynamic diameter, which when large 
enough will cause substantial damage to organs when the particles attempt to pass 
through.  With sufficient organ damage, death can occur.  Choi et al. determined from in 
vivo studies that cadmium selenide quantum dots with a hydrodynamic diameter <5.5 nm 
underwent rapid urinary excretion, while quantum dots >15 nm were unable to be 
eliminated.17  Moghimi et al. note that in rats, polystyrene microspheres >100 nm were 
physically filtered by the spleen and trapped in the splenic bed.18  From these size criteria, 
it would seem as though <5 nm Tio AuNPs may be small enough for successful renal 
filtration, but previous work in the Cliffel lab showed that Tio AuNPs were not able to 
escape opsonization because their overall negative charge drew in too many opsonins.19  
The maximum tolerable dose (less severe, non-fatal renal damage) in mice was found to 
be 200 µL of 20 µM (23 mg/kg) Tio AuNPs in sterile saline; morbidity and acute renal 
failure were seen in all higher concentration groups, along with heavy particle retention 
in the liver, spleen, and kidneys.19  The particle was largely cleared from the blood and 
urine 8 hours post-injection.   
In addition to size criteria, Choi et al. and Moghimi et al. also note the importance 
of surface charge with regard to clearance.17,18  Nanoparticles with charged surfaces 
attract opsonins more than neutral particles, but if the charge is masked or reduced, 
opsonization can be delayed or even evaded, lengthening circulation time.  Polyethylene 
glycol (PEG) has been shown to eliminate toxicity of nanoparticles by adding protein-
resistant properties to the surface to which it is bound.13-15,19  When opsonins are attracted 
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by the charge of the particles, they encounter and compress the longer PEG ligands, 
forcing them into a denser, higher energy conformation.  A repulsive force is created, 
which balances or overpowers the attractive force of the opsonins, effectively shielding 
the particle.  Longer chain-length PEG is associated with stronger protein repulsion.   
 
PEG-ylated Tiopronin AuNPs in vivo 
The Cliffel group has conducted in vivo studies in murine models using Tio 
AuNPs PEG-ylated with a long alkyl chain, alcohol-terminated tetra-EG thiol 
(MUPEG).19  MUPEG-Tio AuNPs eliminated morbidity and renal damage, and remained 
in the bloodstream and urine for the duration of the 4 week study, but still accumulated in 
the liver, spleen, kidneys, and heart.  High concentrations of PEG were shown to produce 
an immune response as determined by red blood cell (RBC) and white blood cell (WBC) 
counts, while lower concentrations did not.  It was reasoned that anti-PEG antibodies 
must have been created in response to the sudden high concentration of PEG, which 
would hinder the particles as a scaffold since the antibody initiates rapid clearance.  A 
carboxylic acid-terminated tetra-EG thiol (PEG4-acid) and an alcohol-terminated tetra-
EG thiol (PEG4OH)20 were placed exchanged onto Tio AuNPs and studied in vivo to 
determine whether a short chain PEG would be capable of shielding the negative charge 
of tiopronin from opsonins, and additionally, if the terminus played an important role in 
circulation time and organ residence.  The exchange rate of PEG was controlled so as not 
to provoke the immune system.  However, Armstrong et al. reported that 25% of normal 
human blood donors have a naturally occurring anti-PEG antibody,21 so any vaccine 
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containing PEG would not benefit this group of people making it necessary to explore 
other capping ligands that do not require PEG to eliminate toxicity.   
 
Glutathione AuNPs in vivo 
Glutathione (GSH) is related structurally to tiopronin, as tiopronin is a glycine 
derivative while GSH is a tripeptide consisting of L-cysteine, L-glutamic acid, and 
glycine.  Unlike tiopronin which is generated synthetically, GSH is found naturally 
within the body (0.5-10 mM in animal cells).22  Tiopronin is effectively administered 
orally for treatment of cystinuria whereas oral administration of glutathione has shown no 
increase in intracellular glutathione;23 glutathione is believed to have difficulty crossing 
the gastrointestinal tract.  When administered intravenously, Hahn et al.24 showed by 
using radiography that free GSH was cleared from the bloodstream within minutes, and 
examination of the organs showed the greatest accumulation within the renal tissue.  It 
appeared that free GSH was internalized by the organs from the blood within a matter of 
minutes for biodegradation in the kidney.  This was concurred by Wendel et al.25 where 
free GSH was shown to accumulate in the renal tissue within 20 minutes with a rapid 
shift to the liver for reassembly.  Given the expected organ sequestration of free GSH, a 
GS AuNP would be likely to provide targeting specification.  Additionally, Choi et al. 
note that zwitterionic or neutral organic coatings on nanoparticles prevent serum protein 
adsorption,17 so as a zwitterion, GSH should be able to avoid opsonization without the 
protection of PEG.  After establishing a clearance profile of GS AuNPs, the particles 
were functionalized with loop and linear PA epitope to attempt to elicit anti-PA antibody 
production.   
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Magic-Sized Monolayer-Protected Clusters as Scaffolds 
 Magic-sized MPCs are highly stable nanoclusters with well-defined structures and 
numbers of atoms.10,26,27  They are atomically monodisperse and many have 
subnanometer core diameters.  There is a fundamental difference between MPCs and 
their larger AuNP counterparts in the discrete, molecular-like electronic structure and 
optical properties observed for MPCs.  Clusters ranging from ~10 to ~100 atoms exhibit 
molecular-like HOMO and LUMO electronic features and step-wise optical absorption 
behavior,28 and distinct electronic features in UV-Vis spectroscopy depending on the core 
size are observed.29  The major focus of work in the field of magic-sized clusters thus far 
has been on synthesis, characterization, and the study of their structure and properties 
rather than on their applications.  However, their extreme monodispersity and molecule-
like properties make MPCs a promising candidate for use as a scaffold for biomolecule 
attachment and presentation in vivo.  TioEG MPCs, magic-sized clusters with a mixed 
monolayer of tiopronin and tiopronin esterified with ethylene glycol, were studied in 
mice as is and functionalized with loop and linear PA epitope, as detailed below.   
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CHAPTER II 
 
EXPERIMENTAL 
 
Reagents 
Tetrachloroauric acid trihydrate was synthesized according to the literature30 and 
stored at -20°C.  N-(2-Mercaptopropionyl)-glycine (tiopronin, Sigma), glutathione 
(Sigma), sodium borohydride (Acros Organics), borane-tert-butylamine complex (TBAB, 
Acros Organics), Thiol-dPEG4-acid (Quanta Biodesign), α-cyano-4-hydroxycinnamic 
acid (CHCA, Sigma-Aldrich), Optima nitric acid (Fisher Scientific), hydrochloric acid 
(EMD Chemicals), trace metal grade nitric acid (Fisher Scientific), trace metal grade 
hydrochloric acid (Fisher Scientific), methanol (Fisher Scientific), glacial acetic acid 
(Fisher Scientific), ethylene glycol (Fisher Scientific), deuterium oxide (Cambridge 
Isotope Laboratories, Inc.), sterile phosphate buffered saline (Mediatech), sterile 0.9% 
sodium chloride (Hospira, Inc.), ZAP-OGLOBINTM II Lytic Reagent (Beckman Coulter), 
and Isoton® II diluent (Beckman Coulter) were all used as received.  A Millipore 
filtration system (18 MΩ) was used to purify water.  12-mercapto-3,6,9,12-
tetraoxadocan-1-ol was synthesized based on a modification of literature methods.31   
 
Synthesis of Tiopronin AuNPs 
Tiopronin monolayer-protected gold nanoparticles (Tio AuNPs) were created in a 
3:1 tiopronin/tetrachloroauric acid trihydrate (HAuCl4•3H2O) mole ratio in agreement 
with a modified Brust reaction.8  A mixture of 1 g HAuCl4•3H2O (2.54 mmol) and 1.24 g 
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tiopronin (7.62 mmol) was dissolved in 100 mL 6:1 (v/v) methanol/ acetic acid in a round 
bottom flask at 0°C.  While stirring, 0.95 g (10x mole excess) of NaBH4 (25.40 mmol) 
was added quickly.  The mixture was allowed to stir for 30 minutes so that the reaction 
could go to completion.  Using a rotary vacuum pump, the solvent was removed and the 
nanoparticles were dissolved in water.  The pH was adjusted to ~1 with concentrated HCl 
and the crude nanoparticle solution was transferred to cellulose ester dialysis membrane 
tubing (Thermo Scientific, MWCO 10,000).  The tubing was clamped on both ends and 
floated in 4L deionized water.  Dialysis proceeded for 3 days with stirring, with water 
changes twice daily.  The solution was then removed under vacuum and the resulting 
nanoparticles were characterized.   
 
Place Exchange of PEG onto Tio AuNPs 
 For the PEG4-acid experiments, three tiopronin/PEG feed ratios were used.  30 
mg Tio AuNP was added to a 1.5 mg (15:1), 10 mg (2:1), or 20 mg (1:1) PEG4-acid 
sample in 3 mL of deionized water and allowed to stir for 1 hr.  12-Mercapto-3,6,9,12-
tetraoxadocan-1-ol (PEG4OH) was placed exchanged onto Tio AuNPs using two feed 
ratios.  4 mg Tio AuNP was added to 0.800 mg (2:1) or 0.107 mg (15:1) PEG4OH in 2 
mL deionized water.  Both PEG4OH reactions were stirred for 30 minutes and all samples 
were dialyzed as previously described for 3 days.  NMR samples were prepared in D2O 
and the actual ratios of tiopronin/PEG were determined.   
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Synthesis of GS AuNPs 
Monodentate glutathione (GSH) monolayer-protected gold nanoparticles (GS 
AuNPs) were synthesized in a 3:1 GSH/HAuCl4•3H2O mole ratio in agreement with a 
modified Brust reaction.8  Briefly, 1 g HAuCl4•3H2O (2.54 mmol) and 2.34 g GSH (7.62 
mmol) were codissolved in 100 mL 6:1 (v/v) methanol/acetic acid in a round bottom 
flask at 0°C.  After 30 minutes of stirring, 0.95 g (10x mole excess with respect to gold) 
NaBH4 (25.40 mmol) was added quickly.  The solvent was removed under vacuum and 
the nanoparticle slurry was dissolved in water and filtered through 0.2 micron syringe 
filters to remove aggregates.  The pH of the resulting dark brown nanoparticle solution 
was adjusted to ~2 with concentrated HCl and the solution was transferred to dialysis 
membrane tubing (Thermo Scientific, MWCO 10,000).  The tubing was clamped on both 
ends and floated in 4L deionized water.  Dialysis proceeded for 3 days with stirring, with 
water changes twice daily.  The solution was then removed under vacuum and the 
resulting nanoparticles were characterized.   
Bidentate GS AuNPs were synthesized in a 1:1 GSH/HAuCl4•3H2O mole ratio.  
Briefly, 1 g HAuCl4•3H2O (2.54 mmol) and 0.945 g GSH (2.54 mmol) were codissolved 
in 100 mL methanol in a round bottom flask at 0°C.  Immediately after GSH was 
dissolved, 0.95 g (10x mole excess with respect to gold) NaBH4 (25.40 mmol) was added 
quickly and the solution was allowed to stir for 30 minutes.  MeOH was removed via 
centrifugation, and the particles were washed with MeOH and centrifuged 3x.  After the 
final decantation the particles were dissolved in water and the solution was transferred to 
dialysis membrane tubing (Thermo Scientific, MWCO 10,000).  The tubing was clamped 
on both ends and floated in 4L deionized water.  Dialysis proceeded for 3 days with 
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stirring, with water changes twice daily.  The solution was then removed under vacuum 
and the resulting nanoparticles were characterized.   
 
Synthesis of TioEG MPCs 
Monolayer-protected gold clusters passivated with tiopronin/tiopronin esterified 
with ethylene glycol (TioEG MPCs) were synthesized in a 3:1 tiopronin/HAuCl4•3H2O 
ratio by adding 0.5037 g HAuCl4•3H2O (1.28 mmol) and 0.6367 g tiopronin (3.90 mmol) 
to 40 mL ethylene glycol heated to 70°C.  The reaction was stirred for about 7 minutes 
and reduced with 1.1005 g TBAB (12.7 mmol, 10x mole excess) in 10 mL ethylene 
glycol heated to 55°C.  Stirring proceeded for 1 hr at 70°C upon which the reaction was 
removed from heat and etched with HCl for 4 days at room temperature.  Excess ethylene 
glycol and tiopronin were removed via dialysis for 7 days and the nanoparticles were 
dried down for characterization.   
 
Synthesis of the Peptide Epitope Mimic of the Protective Antigen of B. Anthracis 
 The epitope mimic of the protective antigen (PA) of B. anthracis was synthesized 
using standard continuous-flow Fmoc solid-phase peptide synthesis methods.  The PA 
loop is a 15-mer peptide of the sequence CKYNDKLPLYISNPC.  Linear PA was also 
synthesized by omitting one cysteine, giving the sequence KYNDKLPLYISNPC.  Resin 
(200 mg) was weighed out and soaked for 30 minutes in dimethylformamide (DMF).  
Each amino acid coupling cycle was carried out in six-fold excess with respect to moles 
of resin using 1:1:1:2 amino acid/HBTU/HOBt/DIEA in DMF for 1 hour.  Before each 
new cycle, the resin was washed 3x in DMF, 3x in methanol, and 3x in DMF.  
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Deprotection, or removal of the Fmoc groups, was achieved through treating the resin 
with 20% pipyridine in DMF for 30 minutes and again rinsing three times each with 
DMF, methanol, and again with DMF.  After the last coupling cycle, the peptidyl resin 
was deprotected and rinsed as before with an additional rinsing of DCM three times.  The 
resin was then incubated for 30 minutes in 50% acetic anhydride in DCM to acylate the 
N-terminal amines before being rinsed three times with methanol and dried with vacuum 
filtration.  A 4 mL trifluoroacetic acid (TFA) solution was made with 90% TFA, 5% 
Thioanosole, 3% Anisole, and 2% ethanedithiol (EDT).  The resin was exposed to the 
TFA solution for 1 hour to cleave the peptides from the resin, filtered through glass wool, 
and the peptides were added to chilled ether.  The peptides were purified using reversed-
phase HPLC, frozen in ether, and lyophilized.   
 
Place Exchange of PA onto AuNPs 
For a ligand to peptide feed ratio (L/P) of 25:1 GS/PA, 20 mg GS AuNP was 
added to 1.63 mg loop PA or 1.54 mg linear PA in 6.66 mL deionized water and stirred 
for 3 days at room temperature.  For 25:1 TioEG/PA, 25 mg TioEG MPC was added to 
3.94 mg loop PA or 3.72 mg linear PA in 25 mL deionized H2O at room temperature.  All 
reactions were purified by dialysis for 3-5 days and actual ratios were determined by 
NMR. 
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Nuclear Magnetic Resonance 
1H NMR spectra for concentrated samples of free ligand and nanoparticles 
dissolved in deuterium oxide were collected on a Bruker AV-400 instrument operating at 
400 MHz.   
 
Thermogravimetric Analysis 
An Instrument Specialist TGA-1000 was used to measure the weight change of a 
~4.5 mg sample of nanoparticles in a platinum pan as a function of temperature to 
determine the percent by mass organic composition of the particles.  Nitrogen flow was 
set to 60 mL min-1 and the temperature was ramped from 25-100°C at a rate of 15°C/min, 
100-110°C at a rate of 1°C/min, and then 110-800°C/min at a rate of 20°C/min.   
 
Transmission Electron Microscopy 
A dilute solution of nanoparticles dissolved in 1 mM HCl or deionized H2O was 
dropped onto a 400 mesh copper grid coated with an ultrathin holey carbon film 
purchased from Ted Pella, Inc. and allowed to dry by slow evaporation.  Images of the 
TEM grid were obtained at a magnification of 150,000× using a Philips CM20 instrument 
operating at 200 keV.  The diameters of >100 particles were measured in nanometers 
from the negatives using ImageJ software (NIH, http://rsb.info.nih.gov/ij/) and used to 
determine an average core diameter of the nanoparticles.   
 
  
15 
 
Ion-Mobility Mass Spectrometry 
 In accordance with previous experiments,32 nanoparticle samples were dissolved 
in 10 μL deionized H2O and combined with 100 μL saturated CHCA and 1% NaCl in 
MeOH or up to 1:1 H2O/MeOH depending on AuNP solubility.  A 1 μL portion of each 
was deposited on a stainless steel plate using the dried droplet method.33  All MALDI-
IM-MS analyses were performed using a Synapt HDMS (Waters Corp., Manchester, UK) 
operating in positive ion mode, equipped with a frequency-tripled Nd:YAG (355 nm) 
laser operated at a pulse repetition frequency of 1000 Hz.  Gold-containing ion signals 
were extracted and identified using the MassLynx 4.1(Waters Corp.) software package.  
0.5% relative abundance and 15 ppm mass accuracy cutoffs were used to reduce false 
positive identifications, and the monoisotopic ion abundances for the identified peaks 
were normalized to the expected monoisotopic abundance for each respective ion.  The 
final set of identified peaks was used in quantitation calculations by the application of eq 
1: 
     (1) 
For a nanoparticle with a binary ligand mixture, X and Y, the term on the left denotes the 
mole fraction of ligand X on the entire nanoparticle.  On the right, the numerator is the 
sum of the multiples of the ion count (CX,Y) and the number of X ligands present in each 
respective peak.  The denominator is the sum of the multiples of the ion count (CX,Y) and 
the total number of ligands (X þ Y) present in each respective peak.  Together, these 
represent a mole fraction of the ligand X present on the nanoparticles. 
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Animal Models 
Animals were female, 16-17 week old BALB/cAnNHsd mice weighing 20-22g 
and purchased from Harlan Sprague Dawley, Inc.  The mice were housed under the 
supervision of full-time veterinarians and staff in a Vanderbilt Division of Animal Care 
(DAC) facility which was fully certified by the Association for the Assessment and 
Accreditation of Laboratory Animal Care (AAALAC).  Animals were given ad libitum 
access to food and water and the animal room had a controlled photoperiod of 12 hr on, 
12 hr off.  All procedures were carried out in accordance with an Institutional Animal 
Care and Use Committees (IACUC) approved protocol.  Mice were allowed one week to 
acclimate to their new housing prior to experimentation.  Nanoparticles were dissolved in 
phosphate buffered saline (PBS) or sterile saline and injected subcutaneously.  The two 
dosage concentrations used were 20 mg/kg (3 mg dissolved in 1.5 mL PBS) and 80 
mg/kg (12 mg dissolved in 1.5 mL PBS).  Each mouse was injected with a total volume 
of 200 µL nanoparticle solution.  Baseline blood and urine samples were collected 1 week 
prior to injection (0 week) and at specific time points post-injection.  Blood was drawn 
via submandibular bleeding34 according to NIH bleeding guidelines for mL blood per kg 
body weight that can safely be taken per 2 weeks.35  Urine was collected on cellophane 
sheets while avoiding fecal contamination as described in the literature.36  Blood and 
urine were analyzed for gold content via inductively coupled plasma optical emission 
spectroscopy (ICP-OES) and red and white blood cell counts were determined by Coulter 
Counter or complete blood cell count to monitor immune response.  The mice were 
euthanized 4 or 8 weeks post-injection via CO2 asphyxiation and organs were harvested 
for histology and trace metal analysis.   
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ICP-OES Analysis 
Samples were prepared as previously described19 with modifications.  For mice 
injected with PEG-Tio AuNPs, blood and urine samples were prepared by diluting 5 µL 
of the fluid in 1 mL aqua regia (3:1 hydrochloric acid/ nitric acid,).  The blood samples 
were digested 24 hr in aqua regia before being further diluted in 9 mL 2% nitric acid 
(Optima grade, Fisher Scientific) while the 2% nitric acid was immediately added to the 
urine samples which required no digestion time.  Organs were weighed and dissolved in 
concentrated nitric acid for 48 h and heated to dryness.  The organ residues were then 
reconstituted in 1 mL aqua regia where they were allowed to digest a further 24 h, and 
diluted in 9 mL 2% nitric acid.  Blood and organ samples were centrifuged and decanted 
to remove remaining tissue and cells.  The values obtained for the organs were adjusted 
for weight and presented as concentration per gram organ.  For mice injected with GS 
AuNPs and TioEG MPCs, trace metal grade nitric and hydrochloric acids were used to 
make aqua regia.  Biological samples were diluted with 10% aqua regia in water.  
Measurements were made on a Perkin-Elmer ICP-OES Optima 700 DV using a Burgener 
Peek Mira Mist® nebulizer with an argon plasma flow of 15 L min-1, nebulizer flow of 
0.65 L min-1, auxiliary flow of 0.2 L min-1, pump flow of 1.6 mL min-1, RF power at 
1450 W, and a delay time of 30 s.  Spectra were collected at a wavelength of 267.595 nm 
in triplicate and averaged.   
 
Coulter Counter Analysis 
Blood was analyzed on a Beckman Z1 Coulter Particle Counter.  Samples were 
prepared for cell count analysis by diluting 40 µL whole blood in 20 mL Isoton® II 
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Diluent (Beckman Coulter) for a 1:500 dilution of the blood specimen to be used as the 
WBC solution.  The RBC solution was made by pipetting 200 µL of the WBC solution 
into 19.8 mL diluent to obtain a 1:50,000 dilution.  The WBC solution received 8-10 
drops of ZAP-OGLOBINTM II lytic reagent (Beckman Coulter) and was agitated slowly.  
Red and white blood cell counts were then collected in triplicate and averaged.   
 
Complete Blood Count 
Blood was submitted to the Vanderbilt Comparative Pathology & Research 
Histology, Translational Pathology Shared Resource for complete blood count (CBC).  
20 µL of whole blood samples were analyzed on a FORCYTETM Veterinary Hematology 
Analyzer manufactured by Oxford Science Inc.   
 
Histology 
Organs were excised shortly after euthanasia and sections of kidney were 
immediately fixed in 10% formalin, neutral buffered with 0.03% eosin (Sigma-Aldrich), 
and sent to Vanderbilt University Medical Center Immunohistochemistry Core Lab for 
hematoxylin and eosin (H&E) staining.  The slides were interpreted by K. Salleng, 
D.V.M., Vanderbilt University Division of Animal Care.   
 
Enzyme-Linked Immunosorbent Assay 
 Materials from the Anthrax Protective Antigen 83 ELISA Kit Cat. No. 800-100-
P83 from Alpha Diagnostic were used for all assays.  To each capture antibody-coated 
well, 300 μL wash solution was added and the well plate was left to stand for 5 minutes.  
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The wash solution was dumped and 100 μL of 200 ng/mL PA standard was added to each 
sample well.  100 μL wash solution was added to the blank wells.  After incubation on a 
plate shaker for 2 hr, the solution was dumped and the wells were washed 5x with 200 μL 
wash solution.  In the wells used in the calibration curve, 100 μL 1:100 diluted anti-PA83 
HRP conjugate from the kit was mixed with 0, 10, 25, 50, 75, 90, or 100 μL 1:100 diluted 
unlabeled anti-PA83 antibody 110 (Cat. No. C86110M, Meridian Life Science).  In the 
serum wells, 100 μL HRP antibody was mixed with 100 μL 1:20 diluted serum in the GS 
AuNP studies or 50 μL undiluted serum in the TioEG MPC studies, from mice injected 
with saline, nanoparticle, nanoparticle functionalized with loop PA, and nanoparticle 
functionalized with linear PA.  Blank wells again received 100 μL wash solution.  The 
plate was again incubated for 2 hr, dumped, and washed 5x with wash solution.  To 
activate the fluorescently labeled HRP antibodies, 100 μL TMB substrate was added to 
all wells and allowed to develop in a dark drawer for up to 15 min.  Once wells had 
developed a blue color, 100 μL Stop Solution (1% sulfuric acid) was added to all wells, 
turning them yellow.  The absorbance was measured immediately afterwards at 450 nm.   
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
Characterization of AuNPs 
Nanoparticles were characterized using analysis methods documented in the 
literature:8 NMR, UV-Vis, TGA, and TEM.  In the NMR spectra of free ligands, the 
peaks are sharp and well-defined because the chemical environment of each ligand is 
identical.  Once bound to the nanoparticle surface, the chemical environment of each 
ligand is slightly different with respect to the movement and positions of the surrounding 
bound ligands.  Broadening of the peaks in the NMR spectra of nanoparticles is observed 
because the signals from these varying states are superimposed and overlap.  
Additionally, the broadened peaks of AuNP NMR spectra are characteristic of 
nanoparticles because the rotational motions of the larger object (AuNP vs. free ligand) 
are slower, allowing for longer relaxation times (T2 spin-spin relaxation) and thus broader 
peaks.8,37  The gold core absorbs strongly in the UV region, with rapid decay of 
absorption into the visible.  A broad surface plasmon (SP) band occurs around 520 nm in 
the spectra of solutions containing AuNPs that increases in intensity with increasing 
average core diameters.9  The absence of a SP band is characteristic of very small 
particles with diameters less than ~5 nm.  TGA analysis allows for the rough 
determination of percent organic and percent gold composition of the nanoparticle 
sample.  Mass is plotted vs. temperature, so as temperature increases, mass decreases.  
After the initial water loss step, organic matter is lost leaving behind the gold core.  TEM 
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analysis reveals the average core size of the nanoparticle samples. Characterization data 
is shown below.   
In Figure 2A, the protons that correspond to each peak are labeled in green on the 
structure of tiopronin.  There is no peak for the thiol proton because it exchanges with 
deuterium in the polar H2O/D2O solution.  This peak appears when a less polar solvent 
system is used, such as CDCl3/DMSO-d6.  The carboxylic acid proton peak is absent for 
similar reasons.  The amine peak occurs at 8.3 ppm, methylene at 3.9 ppm, methine at 3.6 
ppm, and methyl at 1.4 ppm.  Methine does not appear in the Tio AuNP spectrum 
because it is too close to the gold surface when tiopronin is bound to the nanoparticles.   
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Figure 2. Characterization data for Tio AuNPs. A) 1H NMR spectrum of tiopronin ligand (red) and 
characteristically broadened Tio AuNP spectrum (blue); B) slight bump at ~520 nm in the UV-Vis 
spectrum indicates the presence of a small percentage of clusters or aggregates greater than 5 nm in 
diameter; C) TGA shows initial water loss step, then two organic losses, accounting for 40% of the particle 
mass; D) histogram displaying particle size distribution and representative TEM image showing an average 
particle diameter of 2.1±0.5 nm. 
 
 Characterization data for monodentate and bidentate GS AuNPs are shown in 
Figure 3.  The peaks corresponding to the labeled protons in the glutathione structure are 
labeled in the 1H NMR spectra of GSH (green), and in monodentate (red) and bidentate 
GS AuNPs (blue).  At 8.2 ppm, the amide peak occurs and is present in all three spectra.  
Peaks b, d, e, and f correspond to methylenes while c is due to methine.  The signal of the 
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methylene closest to the thiol, peak d, is quenched in the AuNP spectra because of the 
proximity to the gold surface.  The dissimilarity in magnitude of peaks b and c between 
monodentate and bidentate GS AuNPs is due to a variety of molecule orientations on the 
particle surface and differing packing densities.  In monodentate GS AuNPs, GSH is 
attached to the gold surface by a gold-sulfur bond, while in bidentate GS AuNPs, some 
GSH ligands are not only attached through the sulfur bond, but also through a gold-
nitrogen bond.  This is further evidenced in the depression of peak a in the NMR 
spectrum of bidentate GS AuNPs.  Another discrepancy between the particles born of the 
two syntheses can be found in TGA analysis.  Monodentate GS AuNPs were determined 
to be 59% organic, while bidentate GS AuNPs were only 47% organic.  This may be 
explained by the fact that more ligand was available in the monodentate synthesis where 
a 3:1 ligand/gold ratio was employed compared to the 1:1 ratio used in the bidentate 
synthesis.  The higher availability of GSH and perhaps the differing solvent systems 
allowed for more GSH to attach to the surface of monodentate nanoparticles.  Despite the 
differences in the protecting layers, the average core sizes for the two batches were very 
similar, with 2.7±0.7 nm for monodentate and 2.7±0.6 nm for bidentate GS AuNPs.   
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Figure 3. Characterization data for GS AuNPs. A) 1H NMR spectra of GSH ligand (green), and 
monodentate GS AuNPs (red), and bidentate GS AuNPs (blue) showing characteristic peak broadening of 
nanoparticles; B) absence of a SP band at 520 nm in the UV-Vis spectrum indicates particles smaller than 5 
nm in diameter; C) after subtracting water loss in the first weight loss step, the organic loss in the second 
step in TGA analysis accounts for 59% of the total mass in monodentate GS AuNPs, and 47% in bidentate 
GS AuNPs 2; D) representative TEM image showing an average particle diameter of 2.7 + 0.7 nm.   
 
 Using NMR quantification, the ratio of ligand to peptide (L/P) on the nanoparticle 
surface was determined.  The two peaks at 2.2 and 2.5 correspond to 4 methylene protons 
in glutathione, and the small peak around 0.8 ppm is from the 18 methyl protons from 
leucine and isoleucine in PA.  In each spectrum, both of these peaks were integrated and 
the PA peak was calibrated to 18.  The area of the two glutathione peaks was divided by 
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4 and the PA peak was divided by 18 to give an actual L/P.  For loop PA-GS AuNPs, the 
ratio was found to be 32:1 GS/PA, while for linear PA-GS AuNPs, the ratio was 40:1 
GS/PA.   
 
 
Figure 4. 1H NMR spectra of bidentate GS AuNPs functionalized with loop PA (green) or linear PA (red) 
compared with non-functionalized GS AuNPs (blue).  NMR quantification yielded a 32:1 L/P ratio for loop 
PA and a 40:1 L/P ratio for linear PA.   
 
 TioEG MPCs were characterized by UV-Vis, IM-MS, NMR, and TEM.  The 
TEM images (not shown) revealed particles that were so small that the resolution of the 
instrument was not high enough to obtain an average core diameter.  However, by 
comparing the UV-Vis spectrum to one published by Nimmala et al.,38 it was deduced 
that the TioEG MPCs were most likely of the formula Au36(SR)23.  Rather than exhibiting 
the surface plasmon band present around 520 nm in larger gold nanomaterials (>5 nm) 
particles <2 nm in size display distinct electronic features in the UV-Vis spectrum.39  IM-
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MS analysis suggested that approximately 50% of the tiopronin ligands on the particle 
surface were esterified with EG.   
 
 
Figure 5. UV-Vis spectrum of TioEG MPCs compared to inset literature UV-Vis spectrum of Au36(SR)23 
magic-sized nanoparticles.  Inset reproduced from Reference 38. 
 
The L/P was determined using the same method described for quantifying GS 
AuNPs, using the large peak around 1.5 ppm corresponding to the three methyl protons in 
tiopronin.  The ratio of TioEG/PA for loop PA was found to be 29:1, and 26:1 for linear 
PA.   
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Figure 6. 1H NMR spectra of TioEG MPCs functionalized with loop PA (green) or linear PA (red) 
compared with non-functionalized TioEG MPCs (blue).  NMR quantification yielded a 29:1 L/P ratio for 
loop PA and a 26:1 L/P ratio for linear PA.   
 
PEG-Tio AuNP Mouse Studies 
 ICP-OES analyses for gold concentration in blood, urine, and organ samples from 
mice injected with PEG4OH-Tio AuNPs or PEG4-acid-Tio AuNPs are shown below in 
Figure 7.  Both types of particles showed a low concentration in the blood and a high 
concentration in the urine in the first 24 hours after injection.  At the 2 and 4 week 
collections of blood and urine, the particle concentration was negligible.  Since the 
majority of both particle types cleared within 24 hours, compared to the previously 
studied MUPEG-Tio AuNPs19 which had an alcohol terminus and a clearance time of >4 
weeks, it is likely that the chain length rather than the terminus affects circulation time.  
Organ analysis revealed a repeat in the trend seen in MUPEG-Tio mixed monolayer 
nanoparticles versus Tio AuNPs:19 while Tio AuNPs accumulated in high concentrations 
in all the organs in question, the PEG-Tio AuNPs had lower concentrations.  In general, 
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the more PEG exchanged onto the particle, the lower the concentration in the organs, the 
exception being the livers of PEG4-acid-Tio AuNP mice where the reverse trend was 
observed.  This implies tunability in organ targeting by adjusting the exchange rate.  
Long chain MUPEG-Tio AuNPs accumulated in the organs and blood in higher 
concentrations than the short chain PEG-Tio AuNPs, but had a lower concentration in the 
urine as it wasn’t being cleared as effectively.  Therefore shorter PEG ligands afford 
shorter clearance time and less organ retention.  A possible explanation of why particles 
coated with smaller amounts of PEG accumulate in the organs at a higher rate is that 
incomplete surface coverage with PEG left charged areas on the nanoparticle surface 
unguarded against opsonins, making the particles more likely to be sequestered in the 
MPS organs than filtered through the renal system because of their increased 
hydrodynamic diameter.   
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Figure 7. Gold concentration measured using ICP-OES in A) blood, B) urine, and C) organs of mice 
injected with PEG4-acid-Tio AuNPs, and in D) blood, E) urine, and F) organs of mice injected with 
PEG4OH-Tio AuNPs.  Samples contained 5 μL biological fluid or whole organ dissolved in 10 mL 10% 
aqua regia.  The 2 and 4 week time-points for blood and urine are not shown for the PEG4-acid studies 
because the measurements were virtually 0 ppb.  Both particle compositions were essentially cleared from 
the blood and urine within 24 hours and were retained in the organs.  Figure modified from Reference 20. 
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 A graphical representation of the blood cell count expressed as the ratio of red 
blood cells (RBC) to white blood cells (WBC) at 0, 2, and 4 weeks post-injection with 
PEG-Tio AuNPs is shown in Figure 8.  MUPEG caused an increase in WBC count at 
high concentrations,19 correlating immune response to PEG concentration.  There is no 
statistically significant change in the RBC:WBC ratio over the four week period for the 
saline group or lowest percent exchange PEG4-acid, indicating no immune response.  At 
60% and 75% PEG4-acid, there is an increase in RBC count at 4 weeks which causes a 
significant change in the RBC:WBC ratio (asterisked, p<0.01).  This does not signify an 
immune response as there was no significant change in WBC count.  No immune 
response was invoked by the particles at either percent PEG4OH coverage.  These results 
suggest that ~10% PEG coverage is sufficient to alleviate nanotoxicity without eliciting 
an immune response.20   
 
 
Figure 8. Coulter Counter analysis of blood from PEG4-acid-Tio AuNP mice (left) and PEG4OH-Tio AuNP 
mice (right) expressed as a ratio of RBC:WBC counts.  For the saline group and 10% PEG4-acid, there is 
no significant change in the ratio, but at 4 weeks post-injection for the 60 and 75% groups, there is an 
increase in RBC count.  There are no changes for either percent place exchange of PEG4OH, suggesting 
that the more neutral PEG4OH is more tolerable in higher concentrations than PEG4-acid.  Reproduced 
from Reference 20.   
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GS AuNP Mouse Studies 
 Monodentate GS AuNPs were seen to exhibit a circulation time of at least 8 
weeks with no renal toxicity, which is promising for in vivo applications.  The first study 
using monodentate nanoparticles was executed using the same timeline as previous PEG 
studies: blood and urine collection at baseline, 30 min, 1 hr, 4 hr, 8 hr, 24 hr, 2 wk, 4 wk 
post-injection, and postmortem organ harvest at 4 weeks.  Within 30 min of injection, the 
blood was clear of nanoparticle, and the urine was clear within 1 hr.  At 4 wk post-
injection, there was a spike in gold concentration in the blood and urine, but by the time 
of analysis, the mice had already been euthanized so it was impossible to further 
investigate.  The 20 mg/kg group had a higher concentration in the organs selected for 
their roles in filtration and high volume blood flow (spleen, kidney, liver, heart) than the 
80 mg/kg group, excluding the liver.  This is possibly accounted for by the higher 
concentration of gold in the urine of the 80 mg/kg mice, showing more clearance of 
particle than the lower concentration group mice.   
A second study was conducted with plans to carry out to 8 weeks to determine 
how long the spike that occurred at 4 weeks would last.  Beginning 3 weeks post-
exposure, the availability of gold in the bloodstream appeared to have a roughly biweekly 
periodicity in which the concentration was high for 2 weeks, low for 2 weeks, and then 
high again for 2 weeks.  The gold concentration in the blood did not rise significantly 
above baseline until 3 weeks post-injection, at which point it reached 42 ppb for 20 
mg/kg and 28 ppb for 80 mg/kg.  A maximum of 86 and 33 ppb was reached for 20 and 
80 mg/kg, respectively, at 4 weeks post-exposure, but by the 5-week mark both dosage 
groups had fallen back near the baseline.  Another spike in gold concentration in the 
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blood occurred 7 weeks post-injection giving values of 30 ppb (20 mg/kg) and 32 ppb (80 
mg/kg).  By the 8-week time-point, the 20 mg/kg group averaged 33 ppb while the 80 
mg/kg group had decreased to 14 ppb.  
 The concentration of gold in the urine exhibited a less well defined periodicity 
that very roughly corresponds to spikes in the gold concentration in blood.  At 24 hours 
and 2 weeks post-injection, the concentration was elevated in the urine while it was near 
baseline in the blood.  This may be due to particle expulsion from renal tissue if the 
particles were immediately sequestered to the organs and thus removed from blood 
circulation.  A slight decrease in gold concentration in the urine was observed at 3 weeks, 
with another small spike at 4 weeks.  Once again, the concentration fell slightly over 
weeks 5 and 6, but reached a maximum of 31 and 46 ppb for 20 and 80 mg/kg at 7 weeks.  
The concentration again fell to 12 ppb (20 mg/kg) and 14 ppb (80 mg/kg) by 8 weeks 
post-exposure.  
 Mice were sacrificed 8 weeks post-injection and organs were excised for gold 
analysis.  The results, corrected for mass difference, show the largest retention of GS 
AuNPs in the liver, followed by the spleen, then the heart and kidney for the 20 mg/kg 
dosage group.  However, the spleen had a slightly higher concentration of gold than the 
liver in the 80 mg/kg group.  Histology of the kidneys for both studies showed no 
significant lesions, and thus no toxicity.   
 The biodistribution data agrees with accounts of free extracellular GSH, which 
report rapid sequestration to the organs, primarily the kidney for hydrolysis and 
reassembly in the liver.25  Free GSH has also been observed in the spleen.24  While the 
GS monolayer is presumed to be responsible for the immediate removal of the GS AuNP 
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from the blood to the organs, AuNPs with other capping ligands20 have also been shown 
to accumulate in the organs.  These nanoparticles cleared steadily from the body and did 
not exhibit the periodic spikes in concentration that the GS AuNP did, so while retention 
in the organs may be a general property of AuNPs, it is clear the protecting ligand also 
affects the behavior of the particles.   
 
 
Figure 9. Gold concentration measured using ICP-OES in A) blood, B) urine, and C) organs of mice 
injected with monodentate GS AuNPs and terminated at 4 weeks post-exposure, and D) blood, E) urine, 
and F) organs of mice terminated 8 weeks after injection.  Samples contained 5 μL biological fluid or 
whole organ dissolved in 10 mL 10% aqua regia.  AuNPs were immediately removed from the blood and 
sequestered to the organs, where they were released back into the blood at certain time-points for clearance.  
For organs obtained 4 weeks post-injection, there is a higher concentration of particles for the 20 mg/kg 
group, except for in the liver.  In the organs collected 8 weeks post-injection, the opposite is seen; the 80 
mg/kg group had a higher residence in all organs.  Error bars are shown for the organs (n=5) and for n=5 
time-points in the blood and urine, but for the time-points of 30 min, 1 hr, 4 hr, 8 hr, and 24 hr, n=1 because 
NIH bleeding guidelines restrict multiple collections of the necessary blood volume from the same mice 
within 1 week. 
35 
 
 The long circulation time of >8 weeks and non-toxicity make GS AuNPs a good 
candidate for use as a pharmaceutical scaffold, in this case, for attachment of a peptide 
epitope mimic.  A third study was performed, this time using bidentate GS AuNPs.  The 
concentration groups consisted of a saline group (0 mg/kg), 80 mg/kg, and two more 80 
mg/kg groups functionalized with loop or linear PA.  Saline and unmodified 80 mg/kg 
groups were carried out to 8 weeks, while the PA conjugated groups were sacrificed at 4 
weeks post-injection because the serum antibody level during the primary response to 
antigens peaks around 2 weeks, and plateaus for several days to several weeks 
afterwards.40   
Bidentate nanoparticles unexpectedly showed a very different clearance profile 
from monodentate GS AuNPs, as evidenced in Figure 10.  At 24 hr post-exposure, there 
was a very low concentration of no more than 5 ppb in the blood, and no more than 8 ppb 
in the urine of all three 80 mg/kg groups.  This is expected to be the tail of a large spike 
during which the nanoparticles were largely cleared through the urine.  In neither the 
blood nor urine was there any measurable gold at any other time-point for the duration of 
the 8 week study.  The fast clearance was further evidenced by the overall lower 
concentration of gold in all measured organs compared to monodentate GS AuNPs.   
 The biodistribution of the PA functionalized and unfunctionalized GS AuNPs was 
also different.  Unmodified particles were most retained by the liver, followed by the 
spleen, heart, and then kidney.  Linear PA particles had roughly the same concentration 
in all organs, with slightly less in the heart; the same applies to loop PA, except that there 
is more than twice as much gold in the kidney than in linear PA and unmodified GS 
AuNPs.  The difference in secondary structure of the loop PA vs. linear somehow causes 
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more loop PA particles to be caught in the kidneys – perhaps the higher rigidity of 
structure makes these particles too large to cross the renal threshold.  Overall, there is less 
gold in the analyzed organs of the PA mice, possibly caused by a redirection of 
nanoparticles to other untested organs because of the difference in the monolayer.   
 
Figure 10. Gold concentration measured using ICP-OES (n=5) in A) blood, B) urine, and C) organs of mice 
injected with bidentate GS AuNPs and terminated at 8 weeks post-exposure, and D) blood, E) urine, and F) 
organs of mice inoculated with loop or linear PA functionalized GS AuNPs terminated 4 weeks after 
injection.  Samples contained 5 μL biological fluid or whole organ dissolved in 10 mL 10% aqua regia.  
AuNPs were immediately removed from the blood and sequestered to the organs, where they presumably 
remained for the duration of the study.  The biodistribution of unmodified GS AuNPs varied from PA 
functionalized particles.  Loop PA AuNPs accumulated more than twice as much in the kidney than linear 
PA and unmodified GS AuNPs.   
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Competitive sandwich ELISA was used to assess antibody production in mice 
inoculated with GS AuNPs, shown in Figure 11.  Blood was pooled from all subjects in 
each concentration group and four replicates of each were analyzed, with sera diluted 
1:20.  The first four bars in the chart represent sera of mice injected with loop and linear 
PA-GS AuNPs, GS AuNPs, and saline.  The next bar is for wells containing no serum, 
giving the highest absorbance because there is no competition for PA binding sites.  Sera-
containing wells experience a decrease in absorbance because of non-specific binding of 
serum proteins.  Presence of anti-PA antibodies produced by inoculated mice would be 
marked by a significant decrease in one sera concentration group above the others, but as 
there is none, it is not likely that such antibodies are present.  The remaining three bars 
represent controls for which no absorbance is expected: no serum and no PA, saline 
serum with no PA, and GS AuNP serum with no PA.   
 
Figure 11. Absorbances measured in ELISA (n=4) for controls and in sera of mice injected with loop and 
linear PA-GS AuNPs, GS AuNPs, and saline.  An immune response would be indicated by a significantly 
lower absorbance in one serum group than the others, but as there is no real difference, there is no evidence 
of anti-PA antibodies the in sera of any inoculated mice. 
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TioEG MPC Mouse Studies 
 ICP-OES analysis of blood, urine, and organs from mice injected with TioEG 
MPCs is shown below in Figure 12.  Most likely due to their subnanometer size, MPCs 
were rapidly cleared from the blood and urine within 24 hours.  A large amount of 
particle was eliminated by filtration evidenced by the high concentration in the urine, 
reaching a maximum of ~1500-2000 ppb in the higher concentration groups at 1 hour 
post-injection.  Heavy retention was observed in the spleen, kidney, liver, lungs, and 
heart.  As was noted for loop PA-GS AuNPs, loop PA-TioEG MPCs also accumulated in 
the kidneys at a higher rate than the other types of particles.  Chen and coworkers41 report 
the positive correlation between the concentration of immunogenic nanoparticle in the 
spleen and the specific antibody response detected.  PA-TioEG MPCs accumulated in 
~3.5x higher concentrations in the spleen than PA-GS AuNPs, increasing the possibility 
of detecting anti-PA antibodies.   
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Figure 12. Gold concentration measured using ICP-OES in A) blood, B) urine, and C) organs of mice 
injected with TioEG MPCs and MPCs conjugated with loop and linear PA.  Samples contained 5 μL 
biological fluid or whole organ dissolved in 10 mL 10% aqua regia.  All MPCs were essentially cleared 
from the blood and urine within 24 hours and were retained in the organs.  Loop PA-TioEG MPCs were 
retained more heavily in the kidney than other particle types.  Error bars are shown for the organs (n=5) and 
for n=5 time-points in the blood and urine, but for the time-points of 30 min, 1 hr, 4 hr, 8 hr, and 24 hr, n=1 
because NIH bleeding guidelines restrict multiple collections of the necessary blood volume from the same 
mice within 1 week. 
 
 For a normal healthy mouse, RBC counts range from 6.36-9.42 x 106 cells/µL, 
and WBC counts range from 1.8-10.7 x 103 cells/µL.  All measurements obtained fell 
within these normal ranges.  The WBC count is shown below in Figure 13 for each MPC 
type.  No immune response is observed as the natural fluctuations in WBC count are not 
outside the tolerable range and no significant trend is noted.  The slight downward trend 
seen in the loop PA MPCs is attributed to natural drift in WBC count, not an effect of 
nanoparticle inoculation.   
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Figure 13. WBC counts obtained by CBC at baseline and 1, 2, 3, and 4 weeks post-exposure.  The normal 
WBC range for mice is 1.8-10.7 x 103 cells/µL; the lower limit is shown as a dotted line on the figure.  No 
immune response is indicated because the natural fluctuations of WBC counts did not fall outside of 
acceptable limits and no trend is observed, the exception being the slight downward trend in the loop PA-
TioEG MPC mice, which is not significant. 
 
 The calibration curve for a control ELISA is shown in Figure 14.  The volume of 
HRP-labeled antibody added to each well was held constant while varied volumes of 
unlabeled antibody 110 were added to each control well.  As the result of competition for 
binding sites on the bound PA protein, the absorbance decreased linearly as increasing 
amounts of unlabeled antibody were added to the labeled antibody.   
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Figure 14. Calibration curve for control ELISA (n=2).  A constant amount of HRP-antibody was mixed 
with increasing amounts of unlabeled antibody 110, resulting in a linear decrease in absorbance as 
unlabeled antibody competed with labeled antibody for binding sites on PA.   
 
 Using a slightly modified version of the competitive sandwich ELISA procedure 
used for testing GS AuNPs, anti-PA antibodies were detected in the sera of mice 
inoculated with loop PA-TioEG MPCs.  The PA standard used in these experiments was 
obtained from List Biological Labs, Inc. and used at 1000 ng/mL concentrations.  In 
Figure 15, the highest absorbance is observed in the control wells containing no serum, as 
there were no serum proteins or other antibodies to block or compete for PA binding sites.  
As before in the GS AuNP studies, blood was pooled from all subjects in each 
concentration group and four replicates of each serum group were used.  The first four 
bars on the graph show absorbances from wells containing 1:50 diluted serum of mice 
inoculated with saline, TioEG MPCs, loop PA-TioEG MPCs, and linear PA-TioEG 
MPCs.  All absorbances were much lower than the no serum control wells because of 
non-specific binding of serum proteins, so the presence of anti-PA antibodies would be 
evidenced in serum wells that had significantly lower absorbances than the saline serum.  
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Conventionally, data with a p value < 0.05 is considered to be statistically significant 
compared to the baseline (saline serum).  While TioEG MPC serum had no significant 
difference from the saline group, the loop PA-TioEG MPC group was significantly 
different at a 99% confidence interval (p=0.0093).  The linear PA-TioEG MPC group 
was also different from saline, but only at a 90% confidence interval (p=0.0738).  This 
would indicate that both groups of mice receiving loop and linear PA were able to 
produce anti-PA antibodies, though the loop PA was the more effective biological mimic.  
The last bar in the graph represents another control having no PA and no serum.   
 
 
Figure 15. Absorbances measured in ELISA for controls and in sera of mice injected with saline, TioEG 
MPCs, loop and linear PA-TioEG MPCs (n=4).  An immune response would be indicated by a significant 
difference in one serum group from the saline group, as seen in the loop PA MPCs (p=0.0093, 99% CI) and 
less significantly (90% CI) in the linear PA MPCs (p=0.0738).  This indicates the presence of anti-PA 
antibodies in sera of mice inoculated with loop and linear PA MPCs.  There is no significant difference 
between the saline group and the TioEG MPC group.  The absorbance for the no serum control was 
measured at 2.51±0.0014 and the no serum/no PA control had an absorbance of 0.0048±0.0059.   
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE WORK 
 
Conclusions 
 The toxicity associated with Tio AuNPs in vivo has been shown to be eliminated 
with PEG-ylation, but high concentrations of PEG invoke an immune response and 
possibly the formation of anti-PEG antibodies.19  To be an effective scaffold, Tio AuNPs 
must be PEG-ylated with a ligand that will allow them to stay in circulation long enough 
for the body to create antibodies to the target epitope without causing an immune 
response to the PEG itself.  Longer chain lengths allow for longer circulation times, so 
PEG4OH and PEG4-acid may not be the ideal ligand choice since both were mostly 
cleared within 24 hours after injection.20  Additionally, alcohol terminated PEG thiols 
seem to be a better choice than carboxylic acid terminated PEG ligands because a higher 
exchange rate was tolerated without a change in blood cell count.   
 GS AuNPs also proved to be non-toxic and have no adverse effects on the mice.  
After rapid removal from the bloodstream to the organs, it appeared that monodentate GS 
AuNPs were expelled from the organs roughly every two weeks beginning three weeks 
post-injection while bidentate particles were presumed to have cleared rapidly.  Though 
the long circulation time of monodentate particles seemed promising for utilization as a 
scaffold, mice inoculated with bidentate particles functionalized with PA did not produce 
detectable anti-PA antibodies.  If the protecting layer of GS was undergoing 
biodegradation in the organs, this may have destabilized the nanoparticles to the point 
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that they were destroyed, releasing PA from their surface and preventing proper 
presentation of the epitope, so no antibodies could form.   
Of the nanoparticles studied in vivo here, we conclude that TioEG MPCs make 
the best candidate for use in creating an adjuvant suitable for presenting the 
conformational peptide epitope of the protective antigen of B. anthracis.  TioEG MPCs 
were only in circulation for 24 hr but this combined with their organ residence, 
particularly the spleen, was sufficient for the mice inoculated with loop, and to a lesser 
extent linear, PA functionalized MPCs to produce antibodies, as determined by ELISA 
data.   
 
Future Work 
In the future we are interested in studying other epitopes conjugated to gold 
nanoparticles.  Cilengitide is a molecule based on the cyclic peptide motif RGDfV that is 
selective for αv integrins, which are important in angiogenesis.  Angiogensis is a common 
target in cancer treatment as new tumors must become quickly vascularized.  We are 
interested in using a modified Cilengitide containing cyclic and linear RGDfV to 
functionalize gold nanoparticles for the purpose of imaging lung tumors and emerging 
metastases with the added side effect of enhanced radiation sensitivity due to absorption 
by the gold core.   
Lung cancer is the most deadly form of cancer with 5-year relative survival rates 
of only 13.6% for men and 17.5% for women.  As radiotherapy plays a central role in 
treatment of non-small cell lung cancer, a better contrast agent for imaging that could 
improve radiation sensitivity would be a much needed development.  Herold et al. have 
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shown in vitro and in vivo proof that gold microspheres introduced to cancer cell lines or 
injected directly into tumors increased the dosage of X-ray radiation received by >40%.42  
However these microspheres were unable to target the tumor cells explicitly.  Popovtzer 
et al. showed in vitro that gold nanorods conjugated to UM-A9 antibodies specifically 
bound to head and neck cancers and effectively increased contrast in CT images by 5x 
compared to untargeted cancer cells and normal cells.43   
 Our first objective will be to synthesize and characterize gold nanoparticles 
conjugated to RGDfV peptide in loop and linear form.  After that, the efficiency of 
nanoparticle binding to cancer cell lines in vitro will be determined and the successful 
nanoparticles will be subsequently studied in vivo as imaging contrast agents for X-ray 
radiography and CT imaging.   
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